Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2007 1
2009 1
2010 3
2011 2
2012 2
2013 3
2015 2
2016 2
2019 2
2020 6
2021 8
2022 4
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
PGC-1α drives small cell neuroendocrine cancer progression towards an ASCL1-expressing subtype with increased mitochondrial capacity.
Varuzhanyan G, Chen CC, Freeland J, He T, Tran W, Song K, Wang L, Cheng D, Xu S, Dibernardo GA, Esedebe FN, Abt ER, Park JW, Memarzadeh S, Graeber T, Shirihai O, Witte O. Varuzhanyan G, et al. Among authors: memarzadeh s. bioRxiv [Preprint]. 2024 Apr 13:2024.04.09.588489. doi: 10.1101/2024.04.09.588489. bioRxiv. 2024. PMID: 38645232 Free PMC article. Preprint.
[68Ga]Ga-FAPI-46 PET in a Borderline Ovarian Tumor.
Unterrainer LM, Memarzadeh S, Moatamed NA, Benz MR, Czernin J, Calais J. Unterrainer LM, et al. Among authors: memarzadeh s. J Nucl Med. 2024 May 1;65(5):820-821. doi: 10.2967/jnumed.123.266732. J Nucl Med. 2024. PMID: 38212069 No abstract available.
Androgen receptor and its correlation with estrogen and progesterone receptors, aimed for identification of cases for future anti-androgen therapy in endometrial cancers.
Moatamed NA, Vahdatshariatpanahi S, Gjertson DW, Sachs CR, Kang Y, Ostrzega N, Huang J, Memarzadeh S. Moatamed NA, et al. Among authors: memarzadeh s. PLoS One. 2023 Sep 19;18(9):e0291361. doi: 10.1371/journal.pone.0291361. eCollection 2023. PLoS One. 2023. PMID: 37725629 Free PMC article.
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gilbert L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, Lim PC, Castro CM, Provencher D, Memarzadeh S, Method M, Wang J, Moore KN, O'Malley DM. Gilbert L, et al. Among authors: memarzadeh s. Gynecol Oncol. 2023 Mar;170:241-247. doi: 10.1016/j.ygyno.2023.01.020. Epub 2023 Feb 1. Gynecol Oncol. 2023. PMID: 36736157 Free article.
Inability of ovarian cancers to upregulate their MHC-class I surface expression marks their aggressiveness and increased susceptibility to NK cell-mediated cytotoxicity.
Chovatiya N, Kaur K, Huerta-Yepez S, Chen PC, Neal A, DiBernardo G, Gumrukcu S, Memarzadeh S, Jewett A. Chovatiya N, et al. Among authors: memarzadeh s. Cancer Immunol Immunother. 2022 Dec;71(12):2929-2941. doi: 10.1007/s00262-022-03192-7. Epub 2022 May 4. Cancer Immunol Immunother. 2022. PMID: 35507102 Free PMC article.
43 results